GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

Home
/
update
/
details

Amrita Hospital in Faridabad Establishes Center of Excellence for CAR T-Cell Therapy

NextEdge Admin

17 Sep 2024

2 min 19 sec

Amrita Hospital, Faridabad, has launched a Centre of Excellence (CoE) for CAR T-cell therapy, a cutting-edge treatment designed to target specific blood cancers like B-cell non-Hodgkin lymphomas and acute lymphoblastic leukemia. The new center aims to provide advanced immunotherapy to patients in the National Capital Region (NCR).

Dr. Sanjeev Singh, Medical Director of Amrita Hospital, emphasized the institution's role as an early adopter of CAR T-cell therapy, noting its pivotal contribution in optimizing these therapies for patients. He highlighted the hospital's evolution from traditional treatments to stem cell transplants and now CAR T-cell therapy, positioning Amrita as a leader in this next-generation cancer treatment.

Dr. Prashant Mehta, Senior Oncologist, stated that the CoE would enhance the accessibility and scalability of CAR T-cell therapies, resulting in more durable remissions for patients in northern India. He also mentioned that the CoE would support Amrita’s clinical and molecular research, expanding CAR T-cell therapy’s application to solid tumors and autoimmune diseases.

Swami Nijamritananda Puri, Administrative Director, underlined the hospital's commitment to providing affordable, innovative healthcare, guided by the vision of accessible treatment for all. He noted the challenges of introducing new therapies but reaffirmed Amrita’s dedication to advancing cancer treatment in India.

Since the CDSCO’s approval of NexCAR19 in October 2023, more than 100 patients have undergone CAR T-cell therapy, with some survivors remaining in remission for over two years, demonstrating the therapy's potential for long-term success.